400 is a magic number for Dendreon investors. It's the level of annualized Provenge sales, in millions, that the company projects will allow them to achieve profitability. However, with today's preliminary fourth-quarter results showing only mid-single-digit growth, progress toward that goal is painstakingly slow. In the following video, Brenton discusses the release in more detail.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon Corp and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.